NRX-201

Exhibitor

Area of exhibition:

Stand

Knowledge-generating body:

Servatrix Biomed S.L. originates from the Autonomous University of Madrid (UAM), where its core scientific knowledge and technology were generated through long-term academic research in biomedical sciences, particularly in the NRF2 pathway and chronic liver disease.

Servatrix Biomed S.L.’s prototype/product is a proprietary NRF2-activating lead compound, currently in preclinical development, designed for the treatment of MASH/NASH.

Country:

Spain

Region:

Community of Madrid

Sectors:

Industrial Biotech

Chemicals

SDG:

SDG03: Good health and well-being

Video Link:

View video here

Applications

The prototype/product developed by Servatrix Biomed S.L. is intended to be used as a prescription therapeutic drug for patients with MASH/NASH, with the practical application of reducing liver fat, inflammation, and oxidative stress to slow or halt disease progression and prevent severe outcomes such as fibrosis, cirrhosis, and liver failure.

Environment & Water

Food & Agro

Health

Industrial Biotech

Medical Devices

Exhibitor

false

Virtual-Experiments

Region

Community of Madrid

Spain

Medical Devices

Industrial Biotech

Exhibitor

false

OncoGuard Liquid Biopsy

Region

Romania

Medical Devices

Industrial Biotech

Exhibitor

false

Tumor Twin

Region

Romania